Abbvie stock forecast 2025 analysts tracking AbbVie stock forecast

Analysts tracking AbbVie stock forecast 2025 highlight the potential impact of Humira’s global biosimilar competition offset by rapid adoption of newer therapies. Dividend yield is expected to maintain around 3.5%–3.8%, appealing to income-focused portfolios seeking stable cash flow. Overseas stock markets today are higher.  The Euro Stoxx 50 rallied to a new record high and is up +1.24%.  China’s Shanghai Composite did not trade and is closed for the week-long Lunar New Year holiday.  Japan’s Nikkei Stock 225 closed up +0.87%. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. Current projections for AbbVie stock forecast 2025 suggest mid-to-high single-digit revenue growth, supported by strategic diversification into oncology and neuroscience. Valuation models from major investment banks peg forward P/E ratios around 14–15, which may position ABBV attractively compared to healthcare sector peers.